Rectal cancer typically necessitates a combination of radiotherapy (RT), chemotherapy, and surgery. The associated functional disorders and reduction in quality of life have led to an increasing interest in organ preservation strategies. Response strongly correlates with RT dose, but dose escalation with external beam remains limited even with modern external beam RT techniques because of toxicity of the surrounding tissues. This study reports on the use of Papillon, an endocavitary Radiotherapy device, in the treatment of rectal cancer. The device delivers low energy X-rays, allowing for safe dose escalation and better complete response rate. Between January 2015 and February 2024, 24 rectal cancer patients were treated with the addition of a boost delivered by Papillon to standard RT, with or without chemotherapy, in an upfront organ preservation strategy. After a median follow-up (FU) of 43 months, the organ preservation rate was 96% (23/24), and the local relapse rate was 8% (2/24). None of our patients developed grade 3 or more toxicities. Our results demonstrate that the addition of Papillon contact RT provides a high rate of local remission with sustained long-term organ preservation, offering a promising alternative to traditional surgical approaches in patients with rectal cancer.
直肠癌通常需要放疗、化疗和手术的综合治疗。由于相关功能障碍及生活质量下降，器官保留策略日益受到关注。治疗效果与放疗剂量密切相关，但即使采用现代外照射技术，因周围组织毒性限制，外照射剂量提升仍有限。本研究报道了使用腔内放疗设备Papillon治疗直肠癌的临床实践。该设备可释放低能量X射线，实现安全剂量提升并提高完全缓解率。2015年1月至2024年2月期间，24例直肠癌患者在前期器官保留策略中，在标准放疗（联合或不联合化疗）基础上接受Papillon增量照射。中位随访43个月后，器官保留率达96%（23/24），局部复发率为8%（2/24）。所有患者均未出现3级及以上毒性反应。研究结果表明，联合Papillon接触放疗可实现高局部缓解率及长期器官保留，为直肠癌患者提供了传统手术方案之外的新选择。
肿瘤(癌症)患者之家